Fig. 3

Down-regulation of MAPKAPK5-AS1 reduces LPS-induced rat cardiomyocyte apoptosis and inflammation. A Cell viability of H9C2 cells was detected after treated with various concentrations of LPS (0, 0.001, 0.01, 0.1, 1, and 10 ng/mL). B The expression of MAPKAPK5-AS1 in H9C2 cells treated by various concentrations of LPS (0, 0.001, 0.01, 0.1, 1, and 10 ng/mL). C The expression of miR-124-3p in H9C2 cells treated with various concentrations of LPS (0, 0.001, 0.01, 0.1, 1, and 10 ng/mL). D MAPKAPK5-AS1 expression in H9C2 cells transfected by si-NC or si-MAPKAPK5-AS1. E Flow cytometry analysis of apoptosis in cells treated with vehicle, LPS, LPS + si-MAPKAPK5-AS1. F Western blot for protein expressions of t-casp3, c-casp3, t-PARP, e-PARP, Bax, Bcl2, and GAPDH in H9C2 cells treated with vehicle, LPS, or LPS + si-MAPKAPK5-AS1. G Western blot for protein expression levels of IL-1β, MCP-1, IL-6, TNF-α, MMP2, and MMP9 in H9C2 cells treated with vehicle, LPS. or LPS + si-MAPKAPK5-AS1. Each column represents the mean ± SEM. Statistical differences were evaluated with One-way ANOVA followed by Tukey’s post-hoc test. *P < 0.05, **P < 0.01, n = 3